

# Analyst

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

## *In Vivo* Histamine Voltammetry in the Mouse Premamillary Nucleus

Cite this: DOI: 10.1039/x0xx00000x

Srimal Samaranayake, Aya Abdalla, Rhiannon Robke, Kevin M. Wood, Anisa Zeqja, and Parastoo Hashemi\*

Received 00th January 2012,

Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

[www.rsc.org/](http://www.rsc.org/)

Histamine plays a major role in the mediation of allergic reactions such as peripheral inflammation. This classical monoamine is also a neurotransmitter involved in the central nervous system but its roles in this context are poorly understood. Studying histamine neurotransmission is important due to its implications in many neurological disorders. The sensitivity, selectivity and high temporal resolution of fast scan cyclic voltammetry (FSCV) offer many advantages for studying electroactive neurotransmitters. Histamine has previously been studied with FSCV; however, the lack of a robust Faradaic electrochemical signal makes it difficult to selectively identify histamine in complex media, as found *in vivo*. In this work, we optimize an electrochemical waveform that provides a stimulation-locked and unique electrochemical signal towards histamine. We describe *in vitro* waveform optimization and a novel *in vivo* physiological model for stimulating histamine release in the mouse premamillary nucleus via stimulation of the medial forebrain bundle. We demonstrate that a robust signal can be used to effectively identify histamine and characterize its' *in vivo* kinetics.

### Introduction

The central nervous system holds four aminergic systems, dopamine, serotonin, norepinephrine and histamine. These messengers are in an intricate chemical interplay with one-another and other neurotransmitters to precisely modulate many aspects of brain function. It is critical to understand the fundamental neurochemistry of these four modulatory systems to better prevent, diagnose and treat brain disorders and diseases. Fast scan cyclic voltammetry (FSCV) at carbon fiber microelectrodes (CFMs) is a uniquely powerful method for *in vivo* analysis. CFMs are biocompatible, cause negligible damage to brain tissue and, because of their kinetically favorable surface kinetics, provide real-time output of electroactive neurotransmitters.

The dopaminergic system has been extensively studied with FSCV over the previous three decades leading to breakthroughs in understanding dopaminergic mechanisms in the brain.<sup>1-3</sup> More recently, FSCV has been recently developed for the detection of serotonin and norepinephrine<sup>4,5</sup> and many important aspects of the two neurotransmitters are thus being unearthed.<sup>6-10</sup> Histamine is also an electroactive amine, and there have been previous reports of histamine induced FSCV signals in mast cells,<sup>11-13</sup> brain tissue slice preparations<sup>14</sup> and *in vivo*,<sup>15</sup> however mechanistic studies on histamine are limited. This is primarily because histamine electrochemistry is complex, and FSCV induced histamine signals are often interpreted via changes in the capacitive current on the

electrode surface. This approach is fully quantitative, however many analytes induce a capacitive change at the electrode surface limiting selectivity and rendering *in vivo* studies very difficult.

Faradaic electrochemistry more selectively identifies analytes because of the unique potential position of redox peaks.<sup>16</sup> In this paper, we discuss the relevance of histamine adsorption to capacitive currents at CFMs. We describe a novel FSCV waveform that generates a robust oxidation peak in response to histamine. We show *in vitro*, that histamine can be detected selectively and with high sensitivity. Finally, we report and verify a robust histamine signature in the mouse premamillary nucleus (PM) in response to medial forebrain bundle (MFB) stimulation.

Our novel FSCV waveform for histamine provides a tool that will enable the same level of investigation for histamine as other, more established brain amines. Histamine's roles in the brain, in particular with respect to disorders in which it is implicated (e.g. Alzheimer's disease) can thus be systematically studied.

### Experimental Section

#### Chemicals and Reagents

Standard solutions were prepared by dissolving histamine dihydrochloride, dopamine hydrochloride, serotonin hydrochloride and adenosine hydrochloride (Sigma-Aldrich, Co., MO, USA) respectively in Tris-buffer. Tris-buffer was constituted thus: 15 mM

H<sub>2</sub>NC(CH<sub>2</sub>)(OH)<sub>3</sub>.HCl, 140 mM NaCl, 3.25 mM KCl, 1.2 mM CaCl<sub>2</sub>, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>.H<sub>2</sub>O, 1.2 mM MgCl<sub>2</sub> and 2.0 mM Na<sub>2</sub>SO<sub>4</sub> at pH=7.4 in deionized water (EMD Chemicals Inc. NJ, USA).

### Carbon-Fiber Microelectrodes (CFMs)

CFMs were fabricated with 7 μm diameter carbon-fibers (Goodfellow Corporation, PA, USA) aspirated in to glass capillaries (0.6 mm external diameter, 0.4 mm internal diameter, A-M systems, Inc., Sequim, WA). A carbon-glass seal was formed via a vertical micropipette puller (Narishige Group, Tokyo, Japan). The exposed length of the carbon fiber was trimmed to 150 μm under an optical microscope. Microelectrodes were electroplated with Nafion as described previously.<sup>4</sup>

### Data Collection/Analysis

Waveform generation was via a PCIe-6341 DAC/ADC card (National Instruments, Austin, TX). Output current was measured by a CHEM-CLAMP potentiostat (Dagan corporation, MN). Custom built software was employed to drive the hardware, collect data and perform analysis including background subtraction, signal averaging and digital filtering (Knowmad Technologies LLC, Tucson, AZ). All potentials are quoted with respect to Ag/AgCl reference electrodes, which were fabricated via electrodeposition of Cl<sup>-</sup> by holding a silver wire (A-M systems, WA) at 4.0 V for 5 s in 1 M HCl. All data represented with error bars represent the standard error of the mean (SEM). Statistical differences were determined using one-tailed student's-t-tests on paired data sets (p<0.45 was taken as statistically different).

### Langmuir Adsorption Isotherms

A CFM was placed into histamine solution of standard concentration and an optimized histamine waveform was applied. An electronic relay (ADG-419, Analog Devices) was used to switch between the applied waveform and a constant potential (-0.5 V) for 10 seconds to allow histamine adsorption at the electrode surface and reach equilibrium. After 10 seconds, the waveform was reapplied, and the first background-subtracted cyclic voltammogram was collected and analyzed for total adsorbed histamine. In house LabVIEW 2012 software integrated the oxidation peak from the background subtracted cyclic voltammogram and Faraday's law was used to convert this to a surface concentration ( $\Gamma_{\text{histamine}}$ ). Measured data was fit to a linearized Langmuir adsorption isotherm as previously described,<sup>17</sup> and  $K$  is the equilibrium constant for adsorption. This experiment was performed in tris buffer (15 mM).

### Flow Injection Analysis

*In vitro* analyses were performed with flow injection analysis (FIA). CFMs were inserted into a flangeless short 1/8 nut (PEEK P-335, IDEX, Middleboro, MA) such that around 2 mm of the tip remained exposed outside of the nut. The microelectrode-containing nut was then fastened into a modified HPLC union (Elbow PEEK 3432, IDEX, Middleboro, MA). The other end of the elbow union was fastened into the out-flowing stream of the FIA buffer and two holes were drilled into the union for incorporation of the reference electrode and for a 'waste' flow stream. Flow was maintained with a syringe infusion pump (kd Scientific, model KDS-410, Holliston, MA) at 2 mL min<sup>-1</sup>. A rectangular pulse of analyte was introduced into the flow stream for 10 s via a six-port HPLC loop injector

(Rheodyne model 7010 valve, VICI, Houston, TX). For calibrations and waveform optimization, analytes were injected in random concentrations order to avoid carry-over effects.

### Potentiometry

The open circuit potential between CFMs and Ag/AgCl was measured using a potentiostat with an integrated high impedance amplifier (eDAQ Pty Ltd, NSW, Australia). 200 μM of histamine was injected onto the CFM in Tris-buffer using FIA at pH = 7.4. Subsequent injections were after potential recovered to base line.

### Animal Surgeries

Handling and surgery on male C57BL/6J mice weighing 20–25 g (Jackson Laboratory, Bar Harbor, ME) were in agreement with The Guide for the Care and Use of Laboratory Animals, approved by the Institutional Animal Care and Use.

Urethane (25% dissolved in 0.9% NaCl solution, Hospira, Lake Forest, IL) was administered via intraperitoneal (i.p.) injection, and stereotaxic surgery (David Kopf Instruments, Tujunga, CA) was performed. A heating pad sustained mouse body temperature around 37 °C (Braintree Scientific, Braintree, MA). Stereotaxic coordinates were taken in reference to bregma. A Nafion modified CFM was inserted into the PM (AP: -2.45, ML: +0.50, DV: -5.45 to -5.55.). A stainless steel stimulating electrode (diameter: 0.2 mm, Plastics One, Roanoke, VA) was positioned into the MFB (AP: -1.07, ML: +1.10, DV: -5.00). 120 biphasic pulses were applied through a linear constant current stimulus isolator (NL800A, Neurolog, Medical Systems Corp., Great Neck, NY). The 60 Hz trains were 350 μA each phase, 2 ms in width, and 2 s in length. An Ag/AgCl reference electrode was implanted into the brain's opposite hemisphere.

### Drugs

Tacrine hydrochloride (2 mg kg<sup>-1</sup>) and thioperamide maleate (20 mg kg<sup>-1</sup>) from TOCRIS bioscience (Bristol, UK) were dissolved in saline respectively and injected i.p. at a volume of 0.6 ml kg<sup>-1</sup>.


## Results and Discussion

### Histamine Adsorption onto CFMs Underlies Capacitive FSCV Current

Histamine has previously been detected in mast cells and neural tissues with FSCV.<sup>11–15</sup> In the majority of these studies, the oxidation peak that appeared at or after the switching potential on the positive wave, as illustrated in **Figure 1**, was used for quantification. **Figure 1Ai** is an FSCV color plot during flow injection of histamine (20 μM) onto a CFM with a serotonin sensitive waveform.<sup>18</sup> The interpretation of color plots is described in detail elsewhere,<sup>19</sup> briefly, potential is displayed on the y-axis, time on the x-axis and current in false color and injection time is denoted by the star.

A cyclic voltammogram (CV) taken from the vertical white dashed line of the color plot displays an oxidation peak at around 0.8 V that appears after the switching potential (on the returning positive scan). In previous work, a stimulation-locked signal in the rat substantia nigra (SNr) displayed a similar CV and was pharmacologically determined to be histamine.<sup>15</sup> In the absence of pharmacology

however, it is not possible to selectively verify histamine with this waveform, this is because other electroactive species give identical CVs. **Figure 1Aii** is a color plot taken during FIA of adenosine (10  $\mu\text{M}$ ). The corresponding CV (**Figure 1B**) is almost identical to that of histamine's. In a region containing both adenosine and histamine, therefore, it is not possible to distinguish between these analytes electrochemically. Furthermore, other work has shown similar CVs for  $\text{H}_2\text{O}_2$  and gonatropin-releasing hormone,<sup>20, 21</sup> further complicating selective histamine detection.




**Figure 1:** A shows color plots for FIA of (i) 20  $\mu\text{M}$  histamine (ii) 10  $\mu\text{M}$  adenosine. B shows CVs extracted from the vertical dashed lines from (i) and (ii).

Histamine electrochemistry is kinetically limited within the oxidation potential window of previously utilized waveforms. In fact the electrochemical oxidation scheme for histamine is not known, presumably because it involves charge transfer. We therefore postulate that the peaks observed in **Figure 1** are due to non-Faradaic processes. These processes arise on the CFM surface when spontaneous adsorption of histamine causes changes in the electrical bilayer. The electrical bilayer on electrode surfaces acts as a capacitor, discharging current into the electrode, particularly at switching potentials. Capacitive or charging currents are a well-known phenomenon in FSCV because of the high scan rates employed.<sup>16</sup> FSCV is background-subtracted, specifically to remove such background charging currents which do not reflect Faradaic processes associated with analytes of interest. However, adsorption of histamine changes the background capacitive current which cannot be subtracted out, this effect manifests as the features in the CVs in **Figure 1**.

In **Figure 2**, FIA was utilized to inject histamine (200  $\mu\text{M}$ ) onto CFMs while the open field potential was measured vs. Ag/AgCl (**Figure 2A**). **Figure 2B** shows that the potential of the CFMs rapidly peaks in response to histamine injections. Because there is no driving potential, this implies that histamine spontaneously adsorbs to and changes the potential of the CFM. The features on histamine's CV in **Figure 1** are likely a consequence of the current that arises from this adsorption. To further verify this histamine adsorption, Langmuir isotherms were constructed for histamine with a previously described method<sup>22</sup> confirming monolayer coverage of the CFM (**Figure 2C**).

While charging current peaks can quantify histamine, little selectivity is offered since many analytes adsorb onto CFMs. We therefore designed a novel waveform to capture histamine electrochemistry before the switching potential.




**Figure 2:** A shows the schematic diagram of the experimental setup used for potentiometric experiments. B shows the experimental potentiometric data for five consecutive injections of histamine (200  $\mu\text{M}$ ) on CFM. C Langmuir isotherm for histamine adsorption on CFMs in Tris buffer.

### Histamine Selective Waveform (HSW)

Histamine contains an imidazole ring and an aliphatic amine group. This molecule's ability to readily bind metals such as Cu,<sup>23, 24</sup> because of its electronegative sites, means that it is readily amenable to oxidation. However histamine electro-oxidation differs from serotonin and dopamine in that it likely involves charge transfer. This mechanism introduces kinetic limitations that have not yet enabled stimulation-locked peaks on the positive direction of the wave in FSCV studies. Therefore preliminary we utilized a triangular waveform and expanded the potential window to cover a large range thereby allowing histamine oxidation to occur within a single scan. Through trial and error we determined that, *in vitro*, a waveform scanning from -0.7 to 1.1 V (resting at -0.7 V at 600  $\text{Vs}^{-1}$ ) provided an oxidation peak during the positive scan. However this waveform was not successful *in vivo*, showing rapid degradation (fouling). By changing the resting potential to -0.5 V, we found that electrode degradation was eliminated and *in vivo* detection was possible. A possible explanation for this phenomenon is that at -0.7 V, fouling species (e.g. proteins) may preferentially adsorb onto the electrode surface.

Our optimized waveform, the histamine selective waveform (HSW), therefore is -0.7 V to 1.1 V, resting at -0.5 V, with a scan rate of 600  $\text{Vs}^{-1}$ . **Figure 3** compares histamine detection with the previously described serotonin waveform<sup>15</sup> to the HSW. **Figure 3A** (serotonin waveform) and C (HSW) show color plots and CVs during FIA of






**Figure 3:** A & C show color plots for FIA of 20 μM histamine with the serotonin and HSW waveforms respectively. CVs extracted from vertical dashed lines are shown on the right. B shows Current vs. time traces from the horizontal dashed lines from color plots. D shows (i) Calibration curve, (ii) Linear dynamic range ( $n=4 \pm \text{SEM}$ ). E Stability of CFM over 50 consecutive injections of 10 μM histamine ( $n=4 \pm \text{SEM}$ ).

histamine (20 μM). The HSW detects histamine oxidation at around +0.3 V vs. Ag/AgCl, and in contrast to the serotonin waveform, this peak occurs before the switching potential on the positive wave. Furthermore, current vs. time traces, extracted from horizontal dashed lines from the color plots (Figure 3B), show that the HSW response is a square injection while the serotonin waveform response does not reach steady state. This makes it possible to more accurately describe histamine *in vivo* kinetics (i.e. histamine clearance kinetics) with the HSW. The HSW has a linear dynamic range up to 20 μM of histamine (Figure 3Dii), a sensitivity of  $0.354 \pm 0.032 \text{ nA}/\mu\text{M}$  and a limit of detection of 1 μM. Finally, histamine measurements with this waveform show good stability, as evidenced by the negligible loss in signal (normalized oxidation current) during 50 successive flow injections of histamine (10 μM) (Figure 3E).

### HSW Selectivity

We sought to develop a waveform to produce a histamine oxidation peak before the switching potential on the positive scan to increase the selectivity of FSCV towards histamine. To assess the selectivity of the waveform *in vitro*, we tested dopamine, serotonin and adenosine, which are electroactive species that are chemically similar to histamine and commonly found in brain regions containing histamine.<sup>25,26, 27</sup> Figure 4 shows CVs obtained during FIA of histamine (20 μM), dopamine (100 nM), serotonin (10 nM) and adenosine (1 μM). These concentrations were chosen to mimic previously reported evoked *in vivo* concentrations.<sup>11, 26, 28</sup> Adenosine's peak still occurs at the switching potential with this waveform and is therefore unlikely to interfere. The oxidation peak for histamine appears at around 0.3 V vs. Ag/AgCl (green dashed line) and is in a different position from dopamine and serotonin oxidation peaks (around 0.5 and 0.6 V vs. Ag/AgCl (red and blue dashed lines), respectively).

The HSW therefore shows good selectivity *in vitro*. However, the *in vivo* matrix is far more complicated than can be reproduced on the bench. We next assessed the ability of our novel waveform to measure histamine *in vivo*.




**Figure 4:** CVs for 20 μM histamine, 100 nM dopamine, 10 nM serotonin and 1 μM adenosine with *in vitro* FIA using HSW on CFMs. Vertical dashed lines indicate potential positions of peaks.

### In Vivo Histamine

Histamine and serotonin were previously found to be co-released in the SNr upon electrical stimulation of the MFB.<sup>15</sup> We were interested in isolating a histamine signal in a novel physiological circuitry involving the histamine cell bodies. Histamine cell bodies are confined to the posterior hypothalamus, the tuberomammillary nucleus (PM), and send their afferents to the forebrain via the

MFB.<sup>29,30, 31</sup> By utilizing a retrograde-stimulation<sup>15</sup> of the MFB, we reasoned that we would be able to detect histamine in the PM since histamine has previously been measured in this region with microdialysis.<sup>32</sup>



**Figure 5:** A shows a representative color plot of in the PM upon MFB stimulation. B shows a representative *in vitro* color plot of histamine (20  $\mu\text{M}$ ) using FIA. C shows [histamine] vs. time extracted from the horizontal dashed line from color plot A. D shows normalized CVs of *in vivo* and *in vitro* (5  $\mu\text{M}$  histamine) signals taken from vertical dashed lines.


**Figure 5A** shows a color plot in the mouse PM upon MFB stimulation (at 5-7 seconds indicated with the blue bar). An event at around 0.3 V vs. Ag/AgCl is clearly visible: a vertical dashed line through the maximum amplitude of this event (at 7 s) provides the CV in **Figure 5D**. When a CV collected for histamine *in vitro* (**Figure 5B**) was normalized and superimposed onto this *in vivo* CV, there was very good agreement between the oxidation peaks at 0.3 V. The additional features of the *in vivo* CV are due to the capacitive changes on the electrodes surface because of changes in the *in vivo* environment (ionic fluxes, pH changes). Where it not for the peak at 0.3V, it would be impossible to disentangle histamine's electrochemistry from this other electrochemistry occurring at the switching potential.

**Figure 5C** shows how histamine changes with time, determined by extracting current vs. time from the horizontal dashed line of the color plot and the calibration curve in **Figure 3D**. Histamine levels elevate in response to electrical stimulation to around 8  $\mu\text{M}$  and then clear after the stimulation, similar in magnitude to histamine release from mast cells.<sup>11</sup> This profile is similar to dopamine and serotonin reuptake.<sup>10, 33</sup> This is an important finding since it implies a similar reuptake system for histamine, however a histamine transporter is yet to be identified.<sup>34</sup>

Although the electrochemistry is supportive of histamine's identity. It is necessary to perform pharmacological experiments to validate the histamine response. Histamine neuropharmacology is not well explored in voltammetry models and there are very few histamine selective compounds that can cross the blood brain barrier. As a first step, we utilized tacrine, a pharmaceutical therapy for Alzheimer's

disease. Tacrine is thought to primarily inhibit acetylcholinesterase, however it also is a potent inhibitor of histamine N-methyltransferase (HNMT) (histamine metabolizing enzyme).<sup>35-37</sup>

**Figure 6** shows the effect on the evoked PM signal (schematic of circuitry shown in **Figure 6A**) upon i.p. tacrine (2 mg  $\text{kg}^{-1}$ )<sup>38</sup> administration ( $n=5$  animals  $\pm$  SEM). Consistent with tacrine's pharmacokinetic profile in rodents,<sup>39</sup> there was a clear effect 50 minutes after administration, whereby the  $t_{1/2}$  of histamine clearance increased significantly from  $10.9 \pm 1.1$  s to  $15.44 \pm 2.6$  s ( $p=0.01$ ) (**Figure 6B**). This is an expected result of inhibition of histamine metabolism: because HNMT is located intracellularly,<sup>40, 41</sup> inhibition of this enzyme raises cystolic histamine levels which slows down the reuptake equilibria back into the cell.



**Figure 6:** A shows the positions of electrodes (stimulation and CFM) in mouse brain. B & D show representative color plots of stimulated release of histamine using HSW - before and after tacrine (2 mg  $\text{Kg}^{-1}$ ) and thioperamide (20 mg  $\text{Kg}^{-1}$ ). C & E show concentration vs. time traces extracted from horizontal dashed line from B & D respectively, ( $n=5 \pm$  SEM). The 2 s stimulation starting at 5 s is shown by the blue bar.

Because tacrine is non-selective, we performed a further pharmacological experiment to verify the PM signal. Thioperamide is a selective H3 receptor antagonist. We would expect thioperamide administration to affect the kinetics of histamine release and clearance via inhibition of these histamine autoreceptors in the PM.<sup>42</sup>

**Figure 6C and D** show that 50 minutes after thioperamide (20 mg kg<sup>-1</sup>),<sup>43</sup> there was a pronounced increase in histamine release from 7.9 ± 2.1 to 11.8 ± 4.6 μM (p=0.02). Increases in evoked release have previously been seen with dopamine and autoreceptor antagonism.<sup>44, 45</sup> A significant increase in the t<sub>1/2</sub> of histamine clearance was also observed from 13.3 ± 3.4 s to 18.8 ± 3.2 s (p=0.03), which was seen in prior studies with serotonin autoreceptor antagonism.<sup>10</sup> The time course of this experiment is also consistent with thioperamide's pharmacokinetics in rodents.<sup>46</sup>

These pharmacological experiments, in addition to the electrochemical characterization allow us to confidently verify the histamine nature of this signal in the PM.

## Conclusion

Histamine has important, but not well studied roles as a neurotransmitter. FSCV is an ideal tool for histamine detection because of its sensitivity, selectivity and high temporal resolution. Previous FSCV studies have not been able to selectively identify histamine because the CV features were due to capacitative processes on the electrode surface that are not selective. Here, we developed the HSW that provides a robust oxidation peak before the switching peak. We described *in vitro* waveform optimization and a novel *in vivo* physiological model for retrograde stimulation of histamine release in the mouse PM. We verified this signal pharmacologically as histamine. This novel FSCV method will enable detailed *in vivo* characterizations of this important neuromodulator.

## Acknowledgements

The authors would like to thank Ellen Strawsine for technical assistance. WSU funded this research. A Rumble fellowship supported Srimal Samaranayake.

## References

1. D. L. Robinson, B. J. Venton, M. L. Heien and R. M. Wightman, *Clinical chemistry*, 2003, 49, 1763-1773.
2. M. W. Howe, P. L. Tierney, S. G. Sandberg, P. E. Phillips and A. M. Graybiel, *Nature*, 2013, 500, 575-579.
3. C. P. Ford, S. C. Gantz, P. E. Phillips and J. T. Williams, *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 2010, 30, 6975-6983.
4. P. Hashemi, E. C. Dankoski, J. Petrovic, R. B. Keithley and R. M. Wightman, *Analytical Chemistry*, 2009, 81, 9462-9471.
5. J. Park, B. M. Kile and R. M. Wightman, *Eur J Neurosci*, 2009, 30, 2121-2133.
6. K. M. Wood and P. Hashemi, *ACS Chem Neurosci*, 2013, DOI: 10.1021/cn4000378.
7. P. Hashemi, E. C. Dankoski, R. Lama, K. M. Wood, P. Takmakov and R. M. Wightman, *Proc Natl Acad Sci U S A*, 2012, 109, 11510-11515.
8. J. Park, P. Takmakov and R. M. Wightman, *J Neurochem*, 2011, 119, 932-944.
9. J. Park, E. S. Bucher, K. Fontillas, C. Owesson-White, J. L. Ariansen, R. M. Carelli and R. M. Wightman, *Biol Psychiatry*, 2013.

10. K. M. Wood, A. Zeqja, H. F. Nijhout, M. C. Reed, J. Best and P. Hashemi, *J Neurochem*, 2014, DOI: 10.1111/jnc.12733.
11. K. Pihel, S. Hsieh, J. W. Jorgenson and R. M. Wightman, *Anal Chem*, 1995, 67, 4514-4521.
12. K. Pihel, S. Hsieh, J. W. Jorgenson and R. M. Wightman, *Biochemistry*, 1998, 37, 1046-1052.
13. E. R. Travis, Y. M. Wang, D. J. Michael, M. G. Caron and R. M. Wightman, *Proc Natl Acad Sci U S A*, 2000, 97, 162-167.
14. S. Y. Chang, T. Jay, J. Munoz, I. Kim and K. H. Lee, *Analyst*, 2012, 137, 2158-2165.
15. P. Hashemi, E. C. Dankoski, K. M. Wood, R. E. Ambrose and R. M. Wightman, *J Neurochem*, 2011, 118, 749-759.
16. A. Bard and L. Faulkner, *Electrochemical Methods: Fundamentals and Applications*, John Wiley & Sons, Inc, 2001.
17. P. Pathirathna, S. Samaranayake, C. W. Atcherley, K. L. Parent, M. L. Heien, S. P. McElmurry and P. Hashemi, *Analyst*, 2014, 139, 4673-4680.
18. B. P. Jackson, S. M. Dietz and R. M. Wightman, *Anal Chem*, 1995, 67, 1115-1120.
19. D. Michael, E. R. Travis and R. M. Wightman, *Anal Chem*, 1998, 70, 586A-592A.
20. A. L. Sanford, S. W. Morton, K. L. Whitehouse, H. M. Oara, L. Z. Lugo-Morales, J. G. Roberts and L. A. Sombers, *Analytical Chemistry*, 2010, 82, 5205-5210.
21. K. M. Glanowska, B. J. Venton and S. M. Moenter, *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 2012, 32, 14664-14669.
22. P. Pathirathna, Y. Yang, K. Forzley, S. P. McElmurry and P. Hashemi, *Anal Chem*, 2012, 84, 6298-6302.
23. A. Torreggiani, M. Tamba, S. Bonora and G. Fini, *Biopolymers*, 2003, 72, 290-298.
24. B. Xerri, J.-P. Flament, H. Petitjean, C. Berthomieu and D. Berthomieu, *The Journal of Physical Chemistry B*, 2009, 113, 15119-15127.
25. E. RICHELSON, *Journal of clinical psychopharmacology*, 1996, 16, 1S-7S.
26. M. L. A. V. Heien, A. S. Khan, J. L. Ariansen, J. F. Cheer, P. E. M. Phillips, K. M. Wassum and R. M. Wightman, *Proceedings of the National Academy of Sciences of the United States of America*, 2005, 102, 10023-10028.
27. A. van Dijk, A. A. Klomp makers, M. G. P. Feenstra and D. Denys, *Journal of Neurochemistry*, 2012, 123, 897-903.
28. B. E. Swamy and B. J. Venton, *Anal Chem*, 2007, 79, 744-750.
29. *Histamine in the Nervous System*, 2008.
30. A. Vanhala, A. Yamatodani and P. Panula, *The Journal of comparative neurology*, 1994, 347, 101-114.
31. S. Auvinen and P. Panula, *The Journal of comparative neurology*, 1988, 276, 289-303.
32. W. L. Russell, D. P. Henry, L. A. Phebus and J. A. Clemens, *Brain Res*, 1990, 512, 95-101.
33. Q. Wu, M. E. A. Reith, R. M. Wightman, K. T. Kawagoe and P. A. Garris, *Journal of Neuroscience Methods*, 2001, 112, 119-133.
34. L. B. Hough, *Progress in neurobiology*, 1988, 30, 469-505.
35. S. Morisset, E. Traiffort and J. C. Schwartz, *Eur J Pharmacol*, 1996, 315, R1-2.
36. A. Musial, M. Bajda and B. Malawska, *Curr Med Chem*, 2007, 14, 2654-2679.
37. O. D. Taraschenko, W. G. Barnes, K. Herrick-Davis, Y. Yokoyama, D. L. Boyd and L. B. Hough, *Methods Find Exp Clin Pharmacol*, 2005, 27, 161-165.
38. M. Nishibori, R. Oishi, Y. Itoh and K. Saeki, *Japanese journal of pharmacology*, 1991, 55, 539-546.
39. M. Telting-Diaz and C. E. Lunte, *Pharmaceutical research*, 1993, 10, 44-48.
40. L. Maintz and N. Novak, *Am J Clin Nutr*, 2007, 85, 1185-1196.
41. H. Pollard, S. Bischoff and J. C. Schwartz, *J Pharmacol Exp Ther*, 1974, 190, 88-99.

- 1 42. R. E. Brown, D. R. Stevens and H. L. Haas, *Prog Neurobiol*,  
2 2001, 63, 637-672.  
3 43. P. Bernaerts, Y. Lamberty and E. Tirelli, *Behavioural Brain*  
4 *Research*, 2004, 154, 211-219.  
5 44. J. M. Kita, L. E. Parker, P. E. Phillips, P. A. Garris and R. M.  
6 Wightman, *J Neurochem*, 2007, 102, 1115-1124.  
7 45. D. Clark, M. Exner, L. J. Furmidge, K. Svensson and C.  
8 Sonesson, *European journal of pharmacology*, 1995, 275,  
9 67-74.  
10 46. F. Bordi, M. Mor, P. V. Plazzi, C. Silva, A. Caretta and G.  
11 Morini, *Farmaco*, 1992, 47, 1095-1103.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60